Saif MW, Shi N, Zelt S. Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. World J Gastroenterol 2009; 15(35): 4415-4422 [PMID: 19764093 DOI: 10.3748/wjg.15.4415]
Corresponding Author of This Article
Muhammad Wasif Saif, MD, Gastrointestinal Cancers Program, Yale Medical Oncology, 800 Howard Avenue, New Haven, CT 06519, United States. wasif.saif@yale.edu
Article-Type of This Article
Brief Articles
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 3 Distribution of patients by chemotherapy regimen and treatment setting 1n (%)
Chemotherapy regimen
Neoadjuvant (n = 84)
Adjuvant (n = 213)
First-line (n = 743)
Second-line (n = 354)
Any setting (n = 1013)
All 5-FU-based regimens
51 (60.7)
140 (65.7)
319 (42.9)
139 (39.3)
540 (53.5)
5-FU monotherapy
16 (19.0)
104 (48.8)
89 (12.0)
68 (19.2)
257 (25.4)
5-FU + platinum
24 (28.6)
19 (8.9)
104 (14.0)
25 (7.1)
163 (16.1)
5-FU + platinum + non-platinum
14 (16.7)
18 (8.5)
96 (12.9)
31 (8.8)
145 (14.3)
5-FU + non-platinum
2 (2.4)
5 (2.3)
30 (4.0)
40 (11.3)
73 (7.2)
Capecitabine-based regimens
4 (4.8)
24 (11.3)
90 (12.1)
72 (20.3)
166 (16.4)
Capecitabine monotherapy
2 (2.4)
18 (8.5)
50 (6.7)
42 (11.9)
105 (10.4)
Capecitabine + platinum
2 (2.4)
1 (0.5)
11 (1.5)
8 (2.3)
19 (1.9)
Capecitabine + platinum + non-platinum
0 (0.0)
6 (2.8)
16 (2.2)
11 (3.1)
31 (3.1)
Capecitabine + non-platinum
0 (0.0)
1 (0.5)
13 (1.7)
19 (5.4)
32 (3.2)
Table 4 Frequency of complications (rate per 1000 person-months) in patients with GEC, by treatment regimen
Complication
5-FU monotherapy
Capecitabine monotherapy
5-FU combination therapy
Capecitabine combination therapy
Any 5-FU regimen
Any capecitabine regimen
Bone marrow
233
110
349
205
307
151
Constitutional symptom
254
108
323
295
293
183
Gastrointestinal tract symptoms
465
183
577
284
529
224
Infection
199
114
268
150
238
131
Skin complications
0
0
2
0
1
0
Other
14
14
22
32
19
22
Any complication
764
336
835
460
806
387
Citation: Saif MW, Shi N, Zelt S. Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. World J Gastroenterol 2009; 15(35): 4415-4422